Premium
The monoacylglycerol lipase inhibitor JZL 184 attenuates LPS ‐induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action
Author(s) -
Kerr DM,
Harhen B,
Okine BN,
Egan LJ,
Finn DP,
Roche M
Publication year - 2013
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2012.02237.x
Subject(s) - am251 , monoacylglycerol lipase , endocannabinoid system , chemistry , pharmacology , cannabinoid receptor , cannabinoid receptor type 2 , anandamide , fatty acid amide hydrolase , cannabinoid , antagonist , receptor , biochemistry , biology
JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL), the enzyme that preferentially catabolizes the endocannabinoid 2-arachidonoyl glycerol (2-AG). Here, we have studied the effects of JZL184 on inflammatory cytokines in the brain and plasma following an acute immune challenge and the underlying receptor and molecular mechanisms involved.